Rebinyn
Payments companies reported to CMS as associated with Rebinyn. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rebinyn, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rebinyn
These are the largest totals companies reported as associated with Rebinyn. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Shayla Bergmann | Beaufort, SC | Pediatric Hematology-Oncology | $25,482.86 |
| Jennifer Domm | Nashville, TN | Pediatric Hematology-Oncology | $20,052.69 |
| Tammuella Chrisentery-Singleton | New Orleans, LA | Pediatric Hematology-Oncology | $18,947.32 |
| Shveta Gupta | Orlando, FL | Pediatric Hematology-Oncology | $11,809.53 |
| Richard Lemons | Salt Lake City, UT | Pediatric Hematology-Oncology | $10,445.71 |
| Dennis Borrero Ramos | Orlando, FL | Pediatric Hematology-Oncology | $8,109.63 |
| Guy Young | Bozeman, MT | Pediatric Hematology-Oncology | $6,700.85 |
| Kim Schafer | Sacramento, CA | Family | $5,359.62 |
| Fernando Corrales-Medina | Miami, FL | Pediatric Hematology-Oncology | $5,076.62 |
| Leslie Soto Velez | San Juan, PR | Pediatrics | $4,718.41 |
Prescribed Rebinyn?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.